NOVEL THERAPY FOR PANCREATIC CANCERS, TARGETING MOLECULAR FOUNDATION
Dr Michael KC Lee,
Medical Oncologist,
Peter MacCallum Cancer Centre,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | February 2026
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
His care philosophy, embodied in his practice name, “Can-Therapy,” promotes a CAN-do approach to CANcer care: empowering patients to thrive beyond cancer through cutting-edge research and personalised, values-driven care. Beyond the clinic, he leads research as a clinician scientist, developing therapeutic strategies that target RNA processing – the molecular blueprint cancer hijacks to fuel its growth and resistance – by altering its sequence is like changing words in a sentence to redefine cancer’s trajectory.
Supported by Pancare Foundation, the Paul Dear Post Doctoral Fellowship and his industry collaboration, his work aims to revolutionise outcomes for patients with this aggressive cancer by targeting its molecular foundation.
He is a recognised expert in pancreatic cancer care, combining research insights with exceptional patient care, while also providing comprehensive treatment for all cancer types.
Source: Supplied
https://orcid.org/0000-0001-8075-3608
-
CASE STUDY Large scale genetic study finds link between Irritable Bowel Syndrome & cardiovascular system
Research published April 2024 in the journal Cellular and Molecular Gastroenterology and Hepatology sheds light on disease mechanisms common to irritable bowel syndrome (IBS) and cardiovascular diseases (CVD).
-
Seeking discoveries in earlier bowel cancer detection
Associate Professor Susan Woods is a cancer research focused on eradicating bowel cancer through earlier detection and investigating the DNA related from colorectal cancer cells. She leads the Gut Cancer Research Group at the University of Adelaide and SAHMRI and with her team is researching new treatments for advanced disease.
-
Applying artificial intelligence to medical imaging for cardiovascular disease detection
Parmida is a software engineer and biomedical scientist whose research focuses on translating novel medical imaging technologies into clinical practice to improve the diagnosis and management of cardiovascular disease.
Her current work applies advanced deep learning techniques to retinal polarization-sensitive optical coherence tomography (PS-OCT) imaging, aiming to generate clinically meaningful biomarkers and predictions of cardiovascular disease. Parmida’s collaboration partners include Fiona Stanley Hospital in Murdoch, Western Australia.
